Investigators found data from the National Notifiable Diseases Surveillance System that showed hepatitis C virus infection rates doubled among women of reproductive age between 2006 and 2014.
Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
Although hepatic vein pressure gradient measurement is an accurate method for evaluation of portal HTN, this technique is invasive and not widely available.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
Based on guidelines issued by the World Health Organizations in 2018, the American College of Physicians has issued best practice advice that simplifies and improves treatment of chronic hepatitis C virus.
Measuring liver stiffness should be considered after anti-viral treatment because it predicts adverse outcomes even beyond routinely available clinical predictors.
Italian investigators conducted a prospective, multicenter study to assess the safety and effectiveness of glecaprevir/pibrentasvir in chronic hepatitis C patients and their subpopulations.
A study published in the Annals of Internal Medicine found transplanting kidneys from hepatitis C virus (HCV)-positive donors to HCV-negative recipients (HCV D+/R-) may be successful with prophylactic treatment with direct-acting antivirals.
Researchers conducted a simulated economic evaluation cohort analyses to assess the cost-effectiveness of HCV screening and compared other screening programs in the United States.
ASCO recommends that patients with newly diagnosed cancer slated to receive systemic anticancer meds be tested for HBV by 3 tests prior to starting therapy.
New CDC guidelines recommend a test-and-treat approach for healthcare personnel who may have been exposed to acute hepatitis C virus infection at work.
Researchers assessed changes among an aging population of people with chronic hepatitis C virus who are treated with DAAs, including the development of comorbidities and changes in liver disease severity.
Routine hepatitis C virus (HCV) testing at federally qualified health centers (FQHCs) would be cost-effective and could improve outcomes for people with HCV infections.
By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.
Researchers found that no patients with concomitant COVID-19 and hepatitis B virus infection progressed to severe or critically ill status during hospitalization, but many had abnormal liver function tests on admission.
Numerous reports have indicated gastrointestinal, cardiovascular, and neurologic manifestations, in addition to the noted respiratory effects, in patients with COVID-19, and up to 50% of patients with COVID-19 may experience hepatic manifestations.
A combined hepatitis A and typhus vaccine in Australia for use in patients aged > 16 years was shown to be well-tolerated in children aged 2 to 16 years.
